Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hansoh Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials for its new antibody-drug conjugate, HS-20110, aimed at treating advanced solid tumors. This development marks a significant step in the company’s innovation efforts, potentially impacting its market position.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.